Application of aerosol therapy in respiratory diseases in children: A Saudi expert consensus.

Citation metadata

From: Annals of Thoracic Medicine(Vol. 16, Issue 2)
Publisher: Medknow Publications and Media Pvt. Ltd.
Document Type: Article
Length: 20,748 words
Lexile Measure: 1880L

Document controls

Main content

Article Preview :

Byline: Adel. Alharbi, Abdullah. Yousef, Saleh. Alharbi, Abdullah. Al-Shamrani, Mansour. Alqwaiee, Mohammed. Almeziny, Yazan. Said, Saleh. Alshehri, Faisal. Alotaibi, Rafat. Mosalli, Khaled. Alawam, Muslim. Alsaadi

The Saudi Pediatric Pulmonology Association (SPPA) is a subsidiary of the Saudi Thoracic Society (STS), which consists of a group of Saudi experts with well-respected academic and clinical backgrounds in the fields of asthma and other respiratory diseases. The SPPA Expert Panel realized the need to draw up a clear, simple to understand, and easy to use guidance regarding the application of different aerosol therapies in respiratory diseases in children, due to the high prevalence and high economic burden of these diseases in Saudi Arabia. This statement was developed based on the available literature, new evidence, and experts' practice to come up with such consensuses about the usage of different aerosol therapies for the management of respiratory diseases in children (asthma and nonasthma) in different patient settings, including outpatient, emergency room, intensive care unit, and inpatient settings. For this purpose, SPPA has initiated and formed a national committee which consists of experts from concerned specialties (pediatric pulmonology, pediatric emergency, clinical pharmacology, pediatric respiratory therapy, as well as pediatric and neonatal intensive care). These committee members are from different healthcare sectors in Saudi Arabia (Ministry of Health, Ministry of Defence, Ministry of Education, and private healthcare sector). In addition to that, this committee is representing different regions in Saudi Arabia (Eastern, Central, and Western region). The subject was divided into several topics which were then assigned to at least two experts. The authors searched the literature according to their own strategies without central literature review. To achieve consensus, draft reports and recommendations were reviewed and voted on by the whole panel.

The morbidity and mortality associated with respiratory diseases in children represent a major health problem all over the world.[1] In Saudi Arabia, respiratory diseases were reported by the Saudi Ministry of Health as the fifth leading cause of death in the Kingdom in 2014.[2] In Saudi Arabia, the contemporary lifestyle, including exposure to tobacco smoke and pets, can be the reason behind the significant increase in the prevalence of bronchial asthma (one of the most common chronic diseases among children) during the past years.[3]

Aerosolized drugs are frequently prescribed since ancient times to patients to treat bronchospasms, decrease airway inflammation, enhance mucus clearance, as well as prevent or treat an infection.[4]

The use of therapeutic aerosol was first proposed by the ancient Egyptians, dating back to ≈1554 BC by heating leaves of a specific plant and inhaling vapors produced during the heating process.[5] Abu'Ali al-Husayn ibn Sina described the use of opium for a variety of diseases, including severe cough by smoking or nasal inhalation.[6] Aerosol therapy was the first to be described for asthma back in India.[7] Hippocrates (460-377 BC) used a pot with a hole in the lid to deliver various vapors to treat several illnesses.[8] Galen of Pergamon, a Greek physician in the early second century, used inhaled powdered drugs to treat...

Source Citation

Source Citation   

Gale Document Number: GALE|A660154805